A Phase 4, Open-label Study to Assess the Feasibility and Efficacy on Motor and Non-motor Symptoms of Switching From Pramipexole or Ropinirole to Rotigotine Transdermal Patch in Subjects With Advanced Idiopathic Parkinson's Disease

Advanced Idiopathic Parkinson's Disease Clinical Trial

Official title:
An Open-Label, Multicenter, Multinational Study to Assess the Feasibility of Switching Therapy From Pramipexole or Ropinirole to the Rotigotine Transdermal System and Its Effect on Motor and Non-Motor Symptoms in Subjects With Advanced Idiopathic Parkinson's Disease Phase 4

Status Completed

Clinical Trial Summary

The purpose of this study is to assess the safety and feasibility of switching subjects with advanced Parkinson's Disease (PD) from Pramipexole or Ropinirole to Rotigotine and to assess the effects of Rotigotine on motor and non-motor symptoms of Parkinson's Disease in subjects switched from previous treatment with either Pramipexole or Ropinirole.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Advanced Idiopathic Parkinson's Disease
Parkinson Disease

Clinical Trial Details

NCT number	NCT01711866
Study type	Interventional
Source	UCB Pharma
Contact
Status	Completed
Phase	Phase 4
Start date	September 2012
Completion date	March 2013

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01744496` - Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain	Phase 4
Terminated	`NCT01519882` - Sleep Efficiency Assessed by Polysomnography (PSG Sleep Lab Testing) in Advanced Parkinson's Disease	Phase 4
Completed	`NCT00141518` - DAPHNE (Duodopa in Advanced Parkinson's: Health Outcomes & Net Economic Impact)	Phase 4